Agreement - January 25, 2018
Alligator contracts Theradex Oncology as clinical CRO
Alligator Biosciencehas appointed Theradex Oncology as CRO for their planned phase I study of ATOR-1015 for the treatment of metastatic cancer. The upcoming clinical phase I study with ATOR-1015 is a first-in-human dose escalation study in patients with metastatic cancer. The study will be conducted at five sites in Sweden and Denmark. “Engaging Theradex is a key step […]